《公司业绩》华润医药(03320.HK)全年纯利近33亿元微升0.3% 末期息增至12仙
华润医药(03320.HK)公布截至去年12月底止全年业绩,营业额2,004.23亿元,按年跌2%。纯利32.97亿元,按年微升0.3%;每股盈利0.52元。派末期息0.12元,对上财年同期派0.11元。
期内集团毛利录322.94亿元,按年减少5.1%,整体毛利率为16.1%,按年下降0.5个百分点,主要由於期内制药业务平均毛利率有所下降,以及毛利率相对高的制药业务收益占比下降所致。
按业务划分,制药业务实现分部收入因受疫情及带量采购叠加影响,按年下跌4.7%至322.07亿元;医药分销分销业务实现分部收入1,688.32亿元,按年减少1.1%;医药零售业务收入则按年微升0.1%至64.67亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.